{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:17:56Z","timestamp":1793161076388,"version":"4.5.0"},"reference-count":66,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:00:00Z","timestamp":1701993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NeuroDeRisk project","award":["821528"],"award-info":[{"award-number":["821528"]}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["821528"],"award-info":[{"award-number":["821528"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union\u2019s Horizon 2020 research and innovation program and European Federation of Pharmaceutical Industries and Associations","award":["821528"],"award-info":[{"award-number":["821528"]}]},{"name":"CHU Clermont-Ferrand","award":["821528"],"award-info":[{"award-number":["821528"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxics"],"abstract":"<jats:p>Blood biomarkers, including neurofilament light chain (NfL), have garnered attention as potential indicators for chemotherapy-induced peripheral neuropathy (CIPN), a dose-limiting adverse effect of neurotoxic anticancer drugs. However, no blood biomarker has been established for routine application or translational research. This pilot study aimed to evaluate a limited panel of blood biomarkers in rat models of CIPN and their correlations with neuropathic pain. CIPN models were induced through repeated injections of oxaliplatin, paclitaxel, bortezomib, and vincristine. Electronic von Frey testing was used to assess tactile allodynia. Post anticancer injections, serum concentrations of 31 proteins were measured. Allodynia thresholds decreased in anticancer-treated animals compared to controls. No consistent modifications were observed in the biomarkers across CIPN models. The most noteworthy biomarkers with increased concentrations in at least two CIPN models were NfL (paclitaxel, vincristine), MCP-1, and RANTES (oxaliplatin, vincristine). Vincristine-treated animals exhibited strong correlations between LIX, MCP-1, NfL, and VEGF concentrations and tactile allodynia thresholds. No single biomarker can be recommended as a unique indicator of CIPN-related pain. Because of the study limitations (single dose of each anticancer drug, young animals, and single time measurement of biomarkers), further investigations are necessary to define the kinetics, specificities, and sensitivities of MCP-1, RANTES, and NfL.<\/jats:p>","DOI":"10.3390\/toxics11121004","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T08:47:26Z","timestamp":1702025246000},"page":"1004","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Exploring Serum Biomarkers for Neuropathic Pain in Rat Models of Chemotherapy-Induced Peripheral Neuropathy: A Comparative Pilot Study with Oxaliplatin, Paclitaxel, Bortezomib, and Vincristine"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6126-6588","authenticated-orcid":false,"given":"David","family":"Balayssac","sequence":"first","affiliation":[{"name":"Direction de la Recherche Clinique et de l\u2019Innovation, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France"},{"name":"INSERM U1107 NEURO-DOL, Universit\u00e9 Clermont Auvergne, F-63000 Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Durif","sequence":"additional","affiliation":[{"name":"Laboratoire de Biochimie et de G\u00e9n\u00e9tique Mol\u00e9culaire, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6459-4800","authenticated-orcid":false,"given":"C\u00e9line","family":"Lambert","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Biostatistiques, Direction de la Recherche Clinique et de l\u2019Innovation, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristelle","family":"Dalbos","sequence":"additional","affiliation":[{"name":"INSERM U1107 NEURO-DOL, Universit\u00e9 Clermont Auvergne, F-63000 Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chapuy","sequence":"additional","affiliation":[{"name":"INSERM U1107 NEURO-DOL, Universit\u00e9 Clermont Auvergne, F-63000 Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Etienne","sequence":"additional","affiliation":[{"name":"Metabolic Adaptations to Exercise under Physiological and Pathological Conditions (AME2P), Universit\u00e9 Clermont Auvergne, F-63000 Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6199-4534","authenticated-orcid":false,"given":"Claire","family":"Demiot","sequence":"additional","affiliation":[{"name":"UR 20218\u2014Neuropathies et Innovations Th\u00e9rapeutiques (NeurIT), Faculties of Medicine and Pharmacy, University of Limoges, F-87025 Limoges, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7542-9520","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Busserolles","sequence":"additional","affiliation":[{"name":"INSERM U1107 NEURO-DOL, Universit\u00e9 Clermont Auvergne, F-63000 Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6681-1610","authenticated-orcid":false,"given":"Vincent","family":"Martin","sequence":"additional","affiliation":[{"name":"Metabolic Adaptations to Exercise under Physiological and Pathological Conditions (AME2P), Universit\u00e9 Clermont Auvergne, F-63000 Clermont-Ferrand, France"},{"name":"Institut Universitaire de France (IUF), F-75000 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7452-315X","authenticated-orcid":false,"given":"Vincent","family":"Sapin","sequence":"additional","affiliation":[{"name":"Laboratoire de Biochimie et de G\u00e9n\u00e9tique Mol\u00e9culaire, CNRS, INSERM, iGReD, CHU Clermont-Ferrand, Universit\u00e9 Clermont Auvergne, F-63000 Clermont-Ferrand, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fphar.2017.00086","article-title":"Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review","volume":"8","author":"Kerckhove","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, Prevalence, and Predictors of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Selvy, M., Pereira, B., Kerckhove, N., Gonneau, C., Feydel, G., P\u00e9torin, C., Vimal-Baguet, A., Melnikov, S., Kullab, S., and Hebbar, M. (2020). Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082400"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"637593","DOI":"10.3389\/fphar.2021.637593","article-title":"Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and Its Impact on Quality of Life: A Single Center Cross-Sectional Study","volume":"12","author":"Selvy","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","article-title":"Systemic Anticancer Therapy-Induced Peripheral and Central Neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for Diagnosis, Prevention, Treatment and Follow-Up","volume":"31","author":"Jordan","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.3747\/co.23.2780","article-title":"Impact of Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer: A Prospective Evaluation at a Single Institution","volume":"23","author":"Dault","year":"2016","journal-title":"Curr. Oncol. Tor. Ont"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1200\/JCO.2009.23.4344","article-title":"Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study","volume":"27","author":"Chibaudel","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1529-8027.2010.00292.x","article-title":"Measures of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review of Psychometric Properties","volume":"15","author":"Griffith","year":"2010","journal-title":"J. Peripher. Nerv. Syst. JPNS"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jpainsymman.2019.07.021","article-title":"Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy","volume":"58","author":"McCrary","year":"2019","journal-title":"J. Pain Symptom Manag."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s00204-020-02755-w","article-title":"Neurofilament Light Chain: A Specific Serum Biomarker of Axonal Damage Severity in Rat Models of Chemotherapy-Induced Peripheral Neurotoxicity","volume":"94","author":"Meregalli","year":"2020","journal-title":"Arch. Toxicol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Balayssac, D., Busserolles, J., Broto, C., Dalbos, C., Prival, L., Lamoine, S., Richard, D., Quintana, M., Herbet, A., and Hilairet, S. (2023). Neurofilament Light Chain in Plasma as a Sensitive Diagnostic Biomarker of Peripheral Neurotoxicity: In Vivo Mouse Studies with Oxaliplatin and Paclitaxel\u2014NeuroDeRisk Project. Biomed. Pharmacother. Biomedecine Pharmacother., 167.","DOI":"10.1016\/j.biopha.2023.115535"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"15593","DOI":"10.1038\/s41598-022-18716-5","article-title":"Neurofilament Light as a Predictive Biomarker of Unresolved Chemotherapy-Induced Peripheral Neuropathy in Subjects Receiving Paclitaxel and Carboplatin","volume":"12","author":"Burgess","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7995","DOI":"10.1038\/s41598-020-64511-5","article-title":"Serum Neurofilament Light Chain Levels as a Biomarker of Neuroaxonal Injury and Severity of Oxaliplatin-Induced Peripheral Neuropathy","volume":"10","author":"Kim","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"750507","DOI":"10.3389\/fphar.2022.750507","article-title":"Mechanisms of Chemotherapy-Induced Neurotoxicity","volume":"13","author":"Was","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.pain.2009.03.024","article-title":"Thermal Hyperalgesia as a Marker of Oxaliplatin Neurotoxicity: A Prospective Quantified Sensory Assessment Study","volume":"144","author":"Attal","year":"2009","journal-title":"Pain"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jpain.2011.04.008","article-title":"Follow-up Psychophysical Studies in Bortezomib-Related Chemoneuropathy Patients","volume":"12","author":"Cata","year":"2011","journal-title":"J. Pain"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/j.pain.0000000000002486","article-title":"Long-Term Alterations in Somatosensory Functioning in Survivors of Childhood Cancer","volume":"163","author":"Tutelman","year":"2022","journal-title":"Pain"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/mus.21323","article-title":"Glial Fibrillary Acidic Protein as a Marker of Axonal Damage in Chronic Neuropathies","volume":"40","author":"Notturno","year":"2009","journal-title":"Muscle Nerve"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.neucli.2019.12.001","article-title":"Nerve Conduction, Circulating Osteopontin and Taxane-Induced Neuropathy in Breast Cancer Patients","volume":"50","author":"Pizzamiglio","year":"2020","journal-title":"Neurophysiol. Clin. Clin. Neurophysiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jpainsymman.2017.04.021","article-title":"Neuropathic Pain and Nerve Growth Factor in Chemotherapy-Induced Peripheral Neuropathy: Prospective Clinical-Pathological Study","volume":"54","author":"Velasco","year":"2017","journal-title":"J. Pain Symptom Manag."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Brandolini, L., d\u2019Angelo, M., Antonosante, A., Cimini, A., and Allegretti, M. (2019). Chemokine Signaling in Chemotherapy-Induced Neuropathic Pain. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20122904"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"626687","DOI":"10.3389\/fimmu.2020.626687","article-title":"Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy","volume":"11","author":"Fumagalli","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_24","first-page":"620","article-title":"Animal Models of Chemotherapy-Evoked Painful Peripheral Neuropathies","volume":"6","author":"Authier","year":"2009","journal-title":"Neurother. J. Am. Soc. Exp. Neurother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4103\/0976-500X.72351","article-title":"Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research","volume":"1","author":"Kilkenny","year":"2010","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pain.2006.09.016","article-title":"Behavioral and Pharmacological Description of Oxaliplatin-Induced Painful Neuropathy in Rat","volume":"128","author":"Ling","year":"2007","journal-title":"Pain"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pain.2004.01.029","article-title":"Ethosuximide Reverses Paclitaxel- and Vincristine-Induced Painful Peripheral Neuropathy","volume":"109","author":"Flatters","year":"2004","journal-title":"Pain"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jphs.2015.08.006","article-title":"Behavioral and Pharmacological Characteristics of Bortezomib-Induced Peripheral Neuropathy in Rats","volume":"129","author":"Yamamoto","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0161-813X(03)00043-3","article-title":"A New Animal Model of Vincristine-Induced Nociceptive Peripheral Neuropathy","volume":"24","author":"Authier","year":"2003","journal-title":"Neurotoxicology"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ferrier, J., Marchand, F., and Balayssac, D. (2016). Assessment of Mechanical Allodynia in Rats Using the Electronic Von Frey Test. BIO-Protoc., 6.","DOI":"10.21769\/BioProtoc.1933"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Selvy, M., Matt\u00e9vi, C., Dalbos, C., Aissouni, Y., Chapuy, E., Martin, P.-Y., Collin, A., Richard, D., Dumontet, C., and Busserolles, J. (2022). Analgesic and Preventive Effects of Donepezil in Animal Models of Chemotherapy-Induced Peripheral Neuropathy: Involvement of Spinal Muscarinic Acetylcholine M2 Receptors. Biomed. Pharmacother., 149.","DOI":"10.1016\/j.biopha.2022.112915"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"16418","DOI":"10.1523\/JNEUROSCI.1537-15.2015","article-title":"Cholinergic Neurotransmission in the Posterior Insular Cortex Is Altered in Preclinical Models of Neuropathic Pain: Key Role of Muscarinic M2 Receptors in Donepezil-Induced Antinociception","volume":"35","author":"Ferrier","year":"2015","journal-title":"J. Neurosci."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Keizer, R.J., Jansen, R.S., Rosing, H., Thijssen, B., Beijnen, J.H., Schellens, J.H.M., and Huitema, A.D.R. (2015). Incorporation of Concentration Data below the Limit of Quantification in Population Pharmacokinetic Analyses. Pharmacol. Res. Perspect., 3.","DOI":"10.1002\/prp2.131"},{"key":"ref_34","unstructured":"Hillsdale, N.J. (1988). Statistical Power Analysis for the Behavioral Sciences, Lawrence Erlbaum Associates. [2nd ed.]."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gadgil, S., Erg\u00fcn, M., van den Heuvel, S.A., van der Wal, S.E., Scheffer, G.J., and Hooijmans, C.R. (2019). A Systematic Summary and Comparison of Animal Models for Chemotherapy Induced (Peripheral) Neuropathy (CIPN). PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0221787"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.conb.2020.02.001","article-title":"Neurofilaments in Disease: What Do We Know?","volume":"61","author":"Gordon","year":"2020","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.expneurol.2018.06.005","article-title":"Neurofilament Light Chain as Disease Biomarker in a Rodent Model of Chemotherapy Induced Peripheral Neuropathy","volume":"307","author":"Meregalli","year":"2018","journal-title":"Exp. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1097\/j.pain.0000000000002963","article-title":"Broad-Spectrum Neuroprotection Exerted by DDD-028 in a Mouse Model of Chemotherapy-Induced Neuropathy","volume":"164","author":"Lucarini","year":"2023","journal-title":"Pain"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Huehnchen, P., Schinke, C., Bangemann, N., Dordevic, A.D., Kern, J., Maierhof, S.K., Hew, L., Nolte, L., K\u00f6rtvelyessy, P., and G\u00f6pfert, J.C. (2022). Neurofilament Proteins as a Potential Biomarker in Chemotherapy-Induced Polyneuropathy. JCI Insight, 7.","DOI":"10.1172\/jci.insight.154395"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/jns.12493","article-title":"Prospectively Assessing Serum Neurofilament Light Chain Levels as a Biomarker of Paclitaxel-Induced Peripheral Neurotoxicity in Breast Cancer Patients","volume":"27","author":"Karteri","year":"2022","journal-title":"J. Peripher. Nerv. Syst. JPNS"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"942960","DOI":"10.3389\/fonc.2022.942960","article-title":"Blood Neurofilament Light Chain as a Biomarker for Monitoring and Predicting Paclitaxel-Induced Peripheral Neuropathy in Patients with Gynecological Cancers","volume":"12","author":"Kim","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1097\/j.pain.0000000000002840","article-title":"Neurofilament Light Chain as a Biomarker of Axonal Damage in Sensory Neurons and Paclitaxel-Induced Peripheral Neuropathy in Patients with Ovarian Cancer","volume":"164","author":"Mortensen","year":"2022","journal-title":"Pain"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00415-022-11377-4","article-title":"Serum Neurofilament Levels Correlate with Electrodiagnostic Evidence of Axonal Loss in Paclitaxel-Induced Peripheral Neurotoxicity","volume":"270","author":"Velasco","year":"2023","journal-title":"J. Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1007\/s00415-023-11624-2","article-title":"Neurofilament Light Chain Levels Indicate Acute Axonal Damage under Bortezomib Treatment","volume":"270","author":"Cebulla","year":"2023","journal-title":"J. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s10753-022-01729-7","article-title":"Multiplex Assessment of Serum Chemokines CCL2, CCL5, CXCL1, CXCL10, and CXCL13 Following Traumatic Brain Injury","volume":"46","author":"Chen","year":"2023","journal-title":"Inflammation"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"107598","DOI":"10.1016\/j.intimp.2021.107598","article-title":"MCP-1: Function, Regulation, and Involvement in Disease","volume":"101","author":"Singh","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_47","first-page":"1154","article-title":"MCP-1 and IL-8 as Pain Biomarkers in Fibromyalgia: A Pilot Study","volume":"12","author":"Ang","year":"2011","journal-title":"Pain Med. Malden Mass"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1067714","DOI":"10.3389\/fimmu.2023.1067714","article-title":"Systemic Inflammatory Markers in Patients with Polyneuropathies","volume":"14","author":"Rausch","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1471-4906(00)01812-3","article-title":"RANTES: A Versatile and Controversial Chemokine","volume":"22","author":"Appay","year":"2001","journal-title":"Trends Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12974-015-0456-8","article-title":"Loss of Intraepidermal Nerve Fiber Density during SIV Peripheral Neuropathy Is Mediated by Monocyte Activation and Elevated Monocyte Chemotactic Proteins","volume":"12","author":"Lakritz","year":"2015","journal-title":"J. Neuroinflamm."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Liu, T.-W., Chen, C.-M., and Chang, K.-H. (2022). Biomarker of Neuroinflammation in Parkinson\u2019s Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084148"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"113519","DOI":"10.1016\/j.expneurol.2020.113519","article-title":"Vincristine- and Bortezomib-Induced Neuropathies\u2014From Bedside to Bench and Back","volume":"336","author":"Geisler","year":"2021","journal-title":"Exp. Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fnmol.2017.00174","article-title":"Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy","volume":"10","author":"Starobova","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/toxsci\/kfaa186","article-title":"Comparative Analysis of Chemotherapy-Induced Peripheral Neuropathy in Bioengineered Sensory Nerve Tissue Distinguishes Mechanistic Differences in Early-Stage Vincristine-, Cisplatin-, and Paclitaxel-Induced Nerve Damage","volume":"180","author":"Pollard","year":"2021","journal-title":"Toxicol. Sci. Off. J. Soc. Toxicol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2023.02.007","article-title":"Comparative Transcriptome of Dorsal Root Ganglia Reveals Distinct Etiologies of Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy in Rats","volume":"516","author":"Sun","year":"2023","journal-title":"Neuroscience"},{"key":"ref_56","first-page":"5059","article-title":"Comparison of Oxaliplatin and Paclitaxel-Induced Neuropathy (Alliance A151505)","volume":"24","author":"Pachman","year":"2016","journal-title":"Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF03033269","article-title":"Assessment of Neurotoxicity Following Repeated Cremophor\/Ethanol Injections in Rats","volume":"3","author":"Authier","year":"2001","journal-title":"Neurotox. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"744085","DOI":"10.3389\/fphar.2021.744085","article-title":"Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients\u2019 Profiles with Oxaliplatin-Induced Peripheral Neuropathy","volume":"12","author":"Kerckhove","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"451","DOI":"10.30802\/AALAS-CM-19-000042","article-title":"A Review of Pain Assessment Methods in Laboratory Rodents","volume":"69","author":"Turner","year":"2019","journal-title":"Comp. Med."},{"key":"ref_60","first-page":"75","article-title":"The Fundamental Role of Morphology in Experimental Neurotoxicology: The Example of Chemotherapy-Induced Peripheral Neurotoxicity","volume":"117","author":"Marmiroli","year":"2012","journal-title":"Ital. J. Anat. Embryol. Arch. Ital. Anat. Ed Embriologia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1038\/srep06370","article-title":"Electrophysiological, Behavioral and Histological Characterization of Paclitaxel, Cisplatin, Vincristine and Bortezomib-Induced Neuropathy in C57Bl\/6 Mice","volume":"4","author":"Boehmerle","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_62","first-page":"4033","article-title":"Prevention, Diagnosis and Management of Chemotherapy-Induced Peripheral Neuropathy: A Cross-Sectional Study of French Oncologists\u2019 Professional Practices","volume":"29","author":"Selvy","year":"2021","journal-title":"Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.2147\/JPR.S414389","article-title":"Exploring Outcome Priorities and Real-Life Management of Chemotherapy-Induced Peripheral Neurotoxicity: A Survey of the Italian Association for the Study of Pain Members","volume":"16","author":"Sardo","year":"2023","journal-title":"J. Pain Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Cavaletti, G., Pizzamiglio, C., Man, A., Engber, T.M., Comi, C., and Wilbraham, D. (2023). Studies to Assess the Utility of Serum Neurofilament Light Chain as a Biomarker in Chemotherapy-Induced Peripheral Neuropathy. Cancers, 15.","DOI":"10.3390\/cancers15174216"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Mizrahi, D., Park, S.B., Li, T., Timmins, H.C., Trinh, T., Au, K., Battaglini, E., Wyld, D., Henderson, R.D., and Grimison, P. (2021). Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy. JAMA Netw. Open, 4.","DOI":"10.1001\/jamanetworkopen.2020.36695"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"683168","DOI":"10.3389\/fpain.2021.683168","article-title":"Impact of Dose, Sex, and Strain on Oxaliplatin-Induced Peripheral Neuropathy in Mice","volume":"2","author":"Warncke","year":"2021","journal-title":"Front. Pain Res."}],"container-title":["Toxics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2305-6304\/11\/12\/1004\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:35:40Z","timestamp":1760132140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2305-6304\/11\/12\/1004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":66,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["toxics11121004"],"URL":"https:\/\/doi.org\/10.3390\/toxics11121004","relation":{},"ISSN":["2305-6304"],"issn-type":[{"value":"2305-6304","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,8]]}}}